Cephalon, A Target Itself, To Acquire Remainder Of ChemGenex
This article was originally published in The Pink Sheet Daily
Executive Summary
Just a week after purchasing oncology company Gemin X, Cephalon is buying the remaining shares of Australian biotech ChemGenex that it does not already own for $163 million.
You may also be interested in...
Teva’s Synribo Clears FDA For Third-Line Chronic Myeloid Leukemia
Omacetaxine, which was originally submitted by ChemGenex as Omapro, demonstrated response rates of 14% to 18% in patients who had failed two or more tyrosine kinase inhibitors. It enters a crowded space that is likely to add a new member, Ariad’s ponatinib, in the coming months.
ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA
DDMAC says that there is no expanded access program for the unapproved leukemia drug Omapro (omacetaxine mepesuccinate), but even if there were one, ChemGenex would not be allowed to promote it.
ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA
DDMAC says that there is no expanded access program for the unapproved leukemia drug Omapro (omacetaxine mepesuccinate), but even if there were one, ChemGenex would not be allowed to promote it.